caa a22 4500 605479062 CHVBK 20210128100408.0 cr unu---uuuuu 210128e20150901xx s 000 0 eng 10.1007/s10741-015-9490-y doi (NATIONALLICENCE)springer-10.1007/s10741-015-9490-y Impact of pre-implant amiodarone exposure on outcomes in cardiac transplant recipients [Elektronische Daten] [Douglas Jennings, Brandon Martinez, Sheila Montalvo, David Lanfear] Amiodarone remains one of the preferred antiarrhythmic medications for patients with advanced heart failure awaiting cardiac transplant. However, the long half-life and rapid redistribution of this agent into donor myocardium expose heart transplant recipients to potential adverse outcomes. In reviewing the current body of literature, we found that pre-operative amiodarone exposure can increase the risk of bradycardia post-transplant; however, this is unlikely to require permanent pacemaker implant. Further, amiodarone has several serious drug-drug interactions with calcineurin inhibitors. Clinicians should therefore consider empiric reduction in initial dosing for tacrolimus or cyclosporine, and carefully monitor blood levels for at least 3months post-transplant. Although the evidence is conflicting, amiodarone exposure pre-operatively may increase the risk of early graft failure and mortality. Amiodarone use should be minimized whenever possible; if amiodarone cannot practically be discontinued in the pre-transplant phase, judicious monitoring for QTc prolongation and ventricular arrhythmia should be implemented after transplant. As most of the studies included in this review suffered from small sample sizes and limited follow-up, additional research in this area is warranted. Springer Science+Business Media New York, 2015 Amiodarone nationallicence Heart transplant nationallicence Graft survival nationallicence Drug interaction nationallicence Bradycardia nationallicence Jennings Douglas Department of Pharmacy, New York-Presbyterian Hospital, Columbia University Medical Center, 622 West 168th Street VC-B, 10032, New York, NY, USA aut Martinez Brandon College of Pharmacy, Nova Southeastern University, 3200 S. University Drive, 33328, Ft. Lauderdale, FL, USA aut Montalvo Sheila College of Pharmacy, Nova Southeastern University, 3200 S. University Drive, 33328, Ft. Lauderdale, FL, USA aut Lanfear David Department of Cardiovascular Medicine, Henry Ford Hospital, 2799W. Grand Blvd., 48202, Detroit, MI, USA aut Heart Failure Reviews Springer US; http://www.springer-ny.com 20/5(2015-09-01), 573-578 1382-4147 20:5<573 2015 20 10741 https://doi.org/10.1007/s10741-015-9490-y text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s10741-015-9490-y text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Jennings Douglas Department of Pharmacy, New York-Presbyterian Hospital, Columbia University Medical Center, 622 West 168th Street VC-B, 10032, New York, NY, USA aut NATIONALLICENCE 700 1- Martinez Brandon College of Pharmacy, Nova Southeastern University, 3200 S. University Drive, 33328, Ft. Lauderdale, FL, USA aut NATIONALLICENCE 700 1- Montalvo Sheila College of Pharmacy, Nova Southeastern University, 3200 S. University Drive, 33328, Ft. Lauderdale, FL, USA aut NATIONALLICENCE 700 1- Lanfear David Department of Cardiovascular Medicine, Henry Ford Hospital, 2799W. Grand Blvd., 48202, Detroit, MI, USA aut NATIONALLICENCE 773 0- Heart Failure Reviews Springer US; http://www.springer-ny.com 20/5(2015-09-01), 573-578 1382-4147 20:5<573 2015 20 10741